M&A Deal Announcement | Tentt Deal Tracker

Halozyme Therapeutics, Inc. has completed the acquisition of Hypercon technology and Surf Bio’s hyperconcentration technology, a healthcare services other business in California, for about $1.4 billion. The acquired drug delivery technology expands Halozyme’s ENHANZE platform, supporting royalty revenue growth tied to subcutaneous biologics and enabled blockbusters. Halozyme’s healthcare M&A strategy in CA acquisitions strengthens its other acquisition pipeline by broadening and diversifying hyperconcentration capabilities used in biopharma development and commercialization. The deal is part of Halozyme’s broader healthcare deals CA program, with 2026 guidance referencing projected total revenue growth and royalty revenue exceeding $1 billion, and with additional ENHANZE and Hypercon development program starts planned.